Abstract
The small vessel vasculitis syndromes, granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic polyangiitis (EGPA) comprise the group referred to cumulatively as antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). The respiratory tract is commonly involved in each of the syndromes. The clinical presentation of pulmonary parenchymal and tracheobronchial inflammation of GPA and MPA is quite heterogeneous. Consequently, the differential diagnosis is broad and includes infection, malignancy, and other autoimmune diseases. Necrotizing granulomatous inflammation is the disease-defining feature of GPA causing lung nodules or mass lesions with or without cavitation, as well as tracheobronchial inflammation, often with subsequent stenosis. Capillaritis presenting clinically as diffuse alveolar hemorrhage is a severe disease manifestation often leading to respiratory failure which occurs in about 25% of patients with GPA or MPA, but is rare in patients with EGPA. MPA with ANCA targeting myeloperoxidase (MPO-ANCA) is sometimes associated with interstitial lung disease, a relationship that remains under investigation. The diagnostic approach for specific clinical presentations is described in this chapter. The disease manifestations caused by active inflammation in the respiratory tract usually responds well to immunosuppressive therapy following standard principles for AAV. However, damage caused by tracheobronchial involvement may require individualized interventions such as dilation procedures or stent placement. The management of diffuse alveolar hemorrhage caused by AAV is discussed in light of recent study results, and a practical approach to patients with interstitial lung disease and MPO-ANCA is proposed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11.
Colby TV, Specks U. Wegener’s granulomatosis in the 1990s--a pulmonary pathologist's perspective. Monogr Pathol. 1993;36:195–218.
Travis WD, Hoffman GS, Leavitt RY, Pass HI, Fauci AS. Surgical pathology of the lung in Wegener’s granulomatosis. Review of 87 open lung biopsies from 67 patients. Am J Surg Pathol. 1991;15(4):315–33.
Travis WD. Common and uncommon manifestations of Wegener’s granulomatosis. Cardiovasc Pathol. 1994;3(3):217–25.
Martinez F, Chung JH, Digumarthy SR, et al. Common and uncommon manifestations of Wegener granulomatosis at chest CT: radiologic-pathologic correlation. Radiographics. 2012;32(1):51–69.
Gibb W, Williams A. Nocardiosis mimicking Wegener’s granulomatosis. Scand J Infect Dis. 1986;18(6):583–5.
Singh A, Chhina D, Soni RK, Kakkar C, Sidhu US. Clinical spectrum and outcome of pulmonary nocardiosis: 5-year experience. Lung India. 2016;33(4):398–403.
Wechsler RJ, Steiner RM, Israel HL, Patchefsky AS. Chest radiograph in lymphomatoid granulomatosis: comparison with Wegener granulomatosis. AJR Am J Roentgenol. 1984;142(1):79–83.
Roschewski M, Wilson WH. Lymphomatoid granulomatosis. Cancer J. 2012;18(5):469–74.
Daum TE, Specks U, Colby TV, et al. Tracheobronchial involvement in Wegener’s granulomatosis. Am J Respir Crit Care Med. 1995;151(2 Pt 1):522–6.
Yates M, Watts R, Bajema I, et al. Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts. RMD Open. 2017;3(1):e000449.
Seo P, Specks U, Keogh KA. Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. J Rheumatol. 2008;35(10):2017–23.
Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–32.
Polychronopoulos VS, Prakash UB, Golbin JM, Edell ES, Specks U. Airway involvement in Wegener’s granulomatosis. Rheum Dis Clin North Am. 2007;33(4):755–75. vi.
Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37(2):187–92.
Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66(2):222–7.
Lionaki S, Blyth ER, Hogan SL, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum. 2012;64(10):3452–62.
Ernst A, Rafeq S, Boiselle P, et al. Relapsing polychondritis and airway involvement. Chest. 2009;135(4):1024–30.
Chiu K, Wright JL. Large and small airway disease related to inflammatory bowel disease. Arch Pathol Lab Med. 2017;141(3):470–3.
Camus P, Colby TV. The lung in inflammatory bowel disease. Eur Respir J. 2000;15(1):5–10.
Polychronopoulos VS, Prakash UBS. Airway involvement in sarcoidosis. Chest. 2009;136(5):1371–80.
Summers RM, Aggarwal NR, Sneller MC, et al. CT virtual bronchoscopy of the central airways in patients with Wegener’s granulomatosis. Chest. 2002;121(1):242–50.
Niles JL, Böttinger EP, Saurina GR, et al. The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition. Arch Intern Med. 1996;156(4):440–5.
Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116(6):488–98.
Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med. 2003;115(4):284–90.
Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 2005;52(9):2926–35.
Comarmond C, Pagnoux C, Khellaf M, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 2013;65(1):270–81.
Cartin-Ceba R, Diaz-Caballero L, Al-Qadi MO, et al. Diffuse alveolar hemorrhage secondary to antineutrophil cytoplasmic antibody-associated vasculitis: predictors of respiratory failure and clinical outcomes. Arthritis Rheumatol. 2016;68(6):1467–76.
Lara AR, Schwarz MI. Diffuse alveolar hemorrhage. Chest. 2010;137(5):1164–71.
De Lassence A, Fleury-Feith J, Escudier E, Beaune J, Bernaudin JF, Cordonnier C. Alveolar hemorrhage. Diagnostic criteria and results in 194 immunocompromised hosts. Am J Respir Crit Care Med. 1995;151(1):157–63.
Maldonado F, Parambil JG, Yi ES, Decker PA, Ryu JH. Haemosiderin-laden macrophages in the bronchoalveolar lavage fluid of patients with diffuse alveolar damage. Eur Respir J. 2009;33(6):1361–6.
Epstein CE, Elidemir O, Colasurdo GN, Fan LL. Time course of hemosiderin production by alveolar macrophages in a murine model. Chest. 2001;120(6):2013–20.
de Prost N, Parrot A, Cuquemelle E, Picard C, Cadranel J. Immune diffuse alveolar hemorrhage: a retrospective assessment of a diagnostic scale. Lung. 2013;191(5):559–63.
Picard C, Cadranel J, Porcher R, et al. Alveolar haemorrhage in the immunocompetent host: a scale for early diagnosis of an immune cause. Respiration. 2010;80(4):313–20.
Berden AE, Ferrario F, Hagen EC, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010;21(10):1628–36.
Berti, A., Cornec-Le Gall E, Cornec D, et al., Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohort. Nephrol Dial Transplant. 2018.
Sethi S, VD D’A, Nast CC, et al. A proposal for standardized grading of chronic changes in native kidney biopsy specimens. Kidney Int. 2017;91(4):787–9.
de Prost N, Parrot A, Picard C, et al. Diffuse alveolar haemorrhage: factors associated with in-hospital and long-term mortality. Eur Respir J. 2010;35(6):1303–11.
Lauque D, Cadranel J, Lazor R, et al. Microscopic polyangiitis with alveolar hemorrhage. A study of 29 cases and review of the literature. Groupe d’Etudes et de Recherche sur les Maladies “Orphelines” Pulmonaires (GERM”O”P). Medicine (Baltimore). 2000;79(4):222–33.
Klemmer PJ, Chalermskulrat W, Reif MS, Hogan SL, Henke DC, Falk RJ. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis. 2003;42(6):1149–53.
Walsh M, Merkel PA, Jayne D. The effects of plasma exchange and reduced-dose glucocorticoids during remission-induction for treatment of severe ANCA-associated vasculitis [abstract]. Arthritis Rheumatol. 2018;70(Suppl 10)
Katsumata Y, Kawaguchi Y, Yamanaka H. Interstitial lung disease with ANCA-associated vasculitis. Clin Med Insights Circ Respir Pulm Med. 2015;9(Suppl 1):51–6.
Alba MA, Flores-Suárez LF, Henderson AG, et al. Interstital lung disease in ANCA vasculitis. Autoimmun Rev. 2017;16(7):722–9.
Borie R, Crestani B. Antineutrophil cytoplasmic antibody-associated lung fibrosis. Semin Respir Crit Care Med. 2018;39(4):465–70.
Kagiyama N, Takayanagi N, Kanauchi T, Ishiguro T, Yanagisawa T, Sugita Y. Antineutrophil cytoplasmic antibody-positive conversion and microscopic polyangiitis development in patients with idiopathic pulmonary fibrosis. BMJ Open Respir Res. 2015;2(1):e000058.
Hozumi H, Oyama Y, Yasui H, et al. Clinical significance of myeloperoxidase-anti-neutrophil cytoplasmic antibody in idiopathic interstitial pneumonias. PLoS One. 2018;13(6):e0199659.
Idiopathic Pulmonary Fibrosis Clinical Research Network, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968–77.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Moura, M.C., Specks, U. (2020). Lung Involvement in ANCA-Associated Vasculitis. In: Sinico, R., Guillevin, L. (eds) Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis. Rare Diseases of the Immune System. Springer, Cham. https://doi.org/10.1007/978-3-030-02239-6_10
Download citation
DOI: https://doi.org/10.1007/978-3-030-02239-6_10
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-02238-9
Online ISBN: 978-3-030-02239-6
eBook Packages: MedicineMedicine (R0)